The treatment options are determined by levels of hormone receptors (ER/PR+/-), epidermal growth factor type 2 receptors (HER2/neu+/-), or the lack of these receptors [triple negative cancers (TNC with ER/PR/HER2 negative)] in the tumor tissue. This evidence concerns the gene ERBB2 and neoplasm.